2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Sunday, October 21, 2018

9:00AM-11:00AM: Abstract Number: 119

Targeting Dysregulated CD38/NAD+ Homeostasis Mitigates Multiple Organ Fibrosis

Systemic Sclerosis and Related Disorders – Basic Science Poster I

9:00AM-11:00AM: Abstract Number: 41

TAS5315, a Novel Bruton’s Tyrosine Kinase Inhibitor, Improves Bone Strength in Mouse Model for Rheumatoid Arthritis

Rheumatoid Arthritis – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 293

Temporal Trends and Factors Associated with Bisphosphonate Drug Holidays

Health Services Research Poster I – ACR/ARHP

9:00AM-11:00AM: Abstract Number: 307

Tenosynovitis on MRI of Bilateral Hands and Its Concordance with Joint Swelling/Tenderness in Patients with Early Rheumatoid Arthritis

Imaging of Rheumatic Diseases Poster I: MRI

9:00AM-11:00AM: Abstract Number: 186

The Accuracy and Potential Impact of a Diagnostic Decision Support System in Rare Disease Cases

Education Poster

9:00AM-11:00AM: Abstract Number: 416

The Association of Biomechanical Change and Pain Catastrophizing with the Chronic Low Back Pain

Orthopedics, Low Back Pain and Rehabilitation Poster – ACR/ARHP

9:00AM-11:00AM: Abstract Number: 426

The Association of Dietary Patterns with Knee Symptoms and MRI Detected Structures in Patients with Knee Osteoarthritis (OA)

Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 482

The Association of Short-Term Ultraviolet Radiation Exposure and Calcinosis in Juvenile Dermatomyositis in the Childhood Arthritis & Rheumatology Research Alliance Registry

Pediatric Rheumatology – Clinical Poster I: Lupus, Sjögren’s Disease, and Myositis

9:00AM-11:00AM: Abstract Number: 717

The Burden of Chronic Kidney Disease in Systemic Lupus Erythematosus (SLE): A Nationwide Epidemiologic Study

Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

9:00AM-11:00AM: Abstract Number: 721

The Burden of Renal Arteriosclerosis in Lupus Nephritis: A Cohort Study Examining Prevalence and Predictors of Renal Arteriosclerosis

Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

9:00AM-11:00AM: Abstract Number: 626

The Comparative Effectiveness of Cycling Tumor Necrosis Factor Inhibitor (TNFi) Versus Swapping to a Nontnfi on Patient-Reported Functional Ability of Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

9:00AM-11:00AM: Abstract Number: 615

The Comparative Observational Study about Efficacy, Safety and Adherence between Tocilizumab and Infliximab in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

9:00AM-11:00AM: Abstract Number: 373

The Effect of an Intensive Controlled 6-Moth Exercise Program with Subsequent 6-Month Follow-up Period in Patients with Idiopathic Inflammatory Myopathies – Preliminary Data

Muscle Biology, Myositis and Myopathies Poster I: Clinical Features and Disease Course

9:00AM-11:00AM: Abstract Number: 223

The Effect of Concomitant Diabetes on RA-Related Outcomes: Results from the Acr’s RISE Registry

Epidemiology and Public Health Poster I: Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 633

The Effect of Guselkumab on Dactylitis: Results from a Phase 2 Study in Patients with Active Psoriatic Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].